
Sign up to save your podcasts
Or
An AHA review: the OPTION, SUMMIT, VANISH 2, SARAH, and CLEAR trials are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. OPTION Trial
For AF, LAA Rivals Anticoagulants After Ablation
https://www.medscape.com/viewarticle/af-laa-rivals-anticoagulants-after-ablation-2024a1000l7n
4 Reasons to Question Percutaneous Left Atrial Appendage Closure After AF Ablation
https://www.medscape.com/viewarticle/4-reasons-question-percutaneous-left-atrial-appendage-2024a1000l0u
II. SUMMIT Trial
Tirzepatide Reduces Heart Failure Events in HFpEF With Obesity
https://www.medscape.com/viewarticle/tirzepatide-reduces-heart-failure-events-hfpef-obesity-2024a1000kx5
III. VANISH Trial
New Trial Result Pushes Past Antiarrhythmic Therapy After MI
https://www.medscape.com/viewarticle/new-trial-result-pushes-past-antiarrhythmic-therapy-after-mi-2024a1000l08
IV. Cardioprotection
Common Heart Failure Drugs Ease Heart Damage During Chemo https://www.medscape.com/viewarticle/common-heart-failure-drugs-ease-heart-damage-during-chemo-2024a1000l14
V. CLEAR trial
Spironolactone Shows Mixed Results in Acute MI
https://www.medscape.com/viewarticle/spironolactone-shows-mixed-results-acute-mi-2024a1000l41
Routine Colchicine or MRA Post-MI: No CLEAR Benefit
https://www.medscape.com/viewarticle/routine-colchicine-or-mra-post-mi-no-clear-benefit-2024a1000la2
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
4.9
817817 ratings
An AHA review: the OPTION, SUMMIT, VANISH 2, SARAH, and CLEAR trials are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. OPTION Trial
For AF, LAA Rivals Anticoagulants After Ablation
https://www.medscape.com/viewarticle/af-laa-rivals-anticoagulants-after-ablation-2024a1000l7n
4 Reasons to Question Percutaneous Left Atrial Appendage Closure After AF Ablation
https://www.medscape.com/viewarticle/4-reasons-question-percutaneous-left-atrial-appendage-2024a1000l0u
II. SUMMIT Trial
Tirzepatide Reduces Heart Failure Events in HFpEF With Obesity
https://www.medscape.com/viewarticle/tirzepatide-reduces-heart-failure-events-hfpef-obesity-2024a1000kx5
III. VANISH Trial
New Trial Result Pushes Past Antiarrhythmic Therapy After MI
https://www.medscape.com/viewarticle/new-trial-result-pushes-past-antiarrhythmic-therapy-after-mi-2024a1000l08
IV. Cardioprotection
Common Heart Failure Drugs Ease Heart Damage During Chemo https://www.medscape.com/viewarticle/common-heart-failure-drugs-ease-heart-damage-during-chemo-2024a1000l14
V. CLEAR trial
Spironolactone Shows Mixed Results in Acute MI
https://www.medscape.com/viewarticle/spironolactone-shows-mixed-results-acute-mi-2024a1000l41
Routine Colchicine or MRA Post-MI: No CLEAR Benefit
https://www.medscape.com/viewarticle/routine-colchicine-or-mra-post-mi-no-clear-benefit-2024a1000la2
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
129 Listeners
13 Listeners
313 Listeners
160 Listeners
488 Listeners
16 Listeners
3,317 Listeners
89 Listeners
133 Listeners
1,071 Listeners
53 Listeners
169 Listeners
506 Listeners
317 Listeners
58 Listeners
24 Listeners
9 Listeners
239 Listeners
409 Listeners
365 Listeners